Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 2013
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will release its fourth quarter and full year 2012 financial results on
Thursday, February 7, 2013 at 7:00 a.m. EST.
Teva will host a conference call and live webcast on the same day, at
8:00 a.m. EST to discuss its fourth quarter and full year 2012 results
and overall business environment. A Question & Answer session will
follow this discussion.
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States and Canada
1-888-771-4371; International 1-847-585-4405; passcode: 34121499.
A live webcast of the call will also be available on Teva's website at: www.tevapharm.com.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until February 14, 2013, at 11:59 p.m. ET by calling
1-888-843-7419 or 1-630-652-3042; passcode: 34121499#.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
largest generic drug maker, with a global product portfolio of
approximately 1,000 molecules and a direct presence in about 60
countries. Teva's branded businesses focus on CNS, oncology, pain,
respiratory and women's health therapeutic areas as well as biologics.
Teva currently employs approximately 46,000 people around the world and
reached $18.3 billion in net revenues in 2011.
Teva IR: Kevin C. Mannix, 215-591-8912 United
States or Joseph Marczely, 267-468-4281 United
States or Tomer Amitai, 972 (3) 926-7656 Israel or PR: Hadar
Vismunski-Weinberg, 972 (3) 926-7687 Israel or Denise
Bradley, 215-591-8974 United States